Clinical Trial: 20343

Trial Status: Open
Disease Type: Leukemia
Trial ID 20343
Sponsor ID LOXO-BTK-20020

A Phase 3 Open-Label, Randomized Study of LOXO-305 Versus Investigator’s Choice of Idelalisib Plus Rituxan or Bendamustine Plus Rituxan in BTK Inhibitor Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Principal Investigator
Mitul Gandhi, MD
5 Locations


Fairfax Office

Gainesville Office

Arlington Office

Alexandria Office

Loudoun Office

Learn More About This Trial
Other Relevant Trials
Trial ID 21287
Sponsor ID Novartis

A phase Ib/II open label dose confirmation, proof of concept study of siremadlin in combination with venetoclax plus azacitidine in unfit adult AML participants who responded sub-optimally to first-line venetoclax plus azacitidine treatment and in participants with newly diagnosed unfit AML presenting with high-risk clinical features (CHDM201I12201)

Principal Investigator
Mitul Gandhi, MD
1 Location
Trial ID DR-01-ONC-001
Sponsor ID Dren Bio

A Multicenter, Open-Label, First-in-Human, Multiple Expansion Cohort, Phase 1/2 Study to Evaluate the Safety and Efficacy of DR-01 in Adult Subjects with Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas